Company Overview and News
The API released its gasoline and distillate inventory data on April 17, 2018. The API reported that US gasoline inventories decreased by 2.4 MMbbls (million barrels) on April 6–13, 2018. Analysts estimate that US gasoline inventories could have declined by ~0.2 MMbbls during the same period.
The API (American Petroleum Institute) released its gasoline inventory data on April 10, 2018. The API reported that US gasoline inventories increased by 2 MMbbls (million barrels) on March 30–April 6, 2018. Market surveys estimate that US gasoline inventories could have declined by ~1.4 MMbbls during the same period.
On April 3, 2018, the API (American Petroleum Institute) released its crude oil inventory report. The API reported that US gasoline inventories increased by 1.1 MMbbls (million barrels) on March 23–30, 2018. Analysts estimate that US gasoline inventories could have dropped by ~1.3 MMbbls during the same period.
WTI (West Texas Intermediate) oil futures contracts for May delivery decreased 1.3% to $64.38 per barrel on March 28, 2018. Brent oil futures fell 0.8% to $69.53 per barrel on the same day. WTI and Brent oil prices declined for the third straight day.
The US Dollar Index depreciated 1.2% to 89.32 on March 20–27, 2018. The US Dollar Index is near a three-year low. US crude oil prices increased ~3% from March 20–27, 2018. A weak dollar supported oil prices during the same period.
The WTI (West Texas Intermediate) crude oil futures contracts for May delivery increased 2.6% to $65.17 per barrel on March 21, 2018. WTI crude oil active futures had the highest settlement since February 2, 2018. Brent oil futures rose 3% to $69.47 per barrel on March 21, 2018. Brent crude oil active futures had the highest settlement since February 1, 2018.
The US Dollar Index appreciated 0.67% to 90.37 on March 20, 2018. The US Dollar Index is near a three-week high ahead of the Fed’s meeting. US crude oil prices increased 2.2% on March 20, 2018. A strong dollar could have limited the upside for oil prices during the same period.
April US crude oil futures contracts rose 0.41% to $60.96 per barrel on March 14, 2018. Brent oil futures also rose 0.39% to $64.89 per barrel on the same day. The United States Oil ETF (USO) and the United States Brent Oil ETF (BNO) follow WTI and Brent oil futures, respectively. USO rose ~0.33% to $12.2 on March 14, 2018, while BNO rose 0.28% to $17.8 on the same day.
The US Dollar Index depreciated 0.3% to 89.6 on March 13, 2018—near a one-week low. Similarly, US crude oil prices decreased 1.1% on March 13, 2018. A weak dollar could have limited the downside for prices during the same period.
April US crude oil futures contracts fell 1.1% to $61.36 per barrel on March 12, 2018. Brent oil futures fell 0.8% to $64.95 per barrel on March 12, 2018.
The EIA estimates that US crude oil production increased 0.8% to a record high of 10,369,000 bpd (barrels per day) on February 23–March 2, 2018. US crude oil production also increased by 1,281,000 bpd or 14.1% YoY (year-over-year).
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET